Email updates

Keep up to date with the latest news and content from Systematic Reviews and BioMed Central.

Open Access Research

Effectiveness of rifaximin and fluoroquinolones in preventing travelers’ diarrhea (TD): a systematic review and meta-analysis

Sanjin Alajbegovic1, John W Sanders2, Deborah E Atherly3 and Mark S Riddle2*

Author Affiliations

1 School of Pharmacy, University of Washington, Seattle, WA, USA

2 Naval Medical Research Center, Silver Spring, 20910-7500, MD, USA

3 PATH, Seattle, WA, USA

For all author emails, please log on.

Systematic Reviews 2012, 1:39  doi:10.1186/2046-4053-1-39

Published: 28 August 2012



Recent developments related to a safe and effective nonabsorbable antibiotic, rifaximin, and identification of postinfectious irritable bowel syndrome as a frequent sequela call for a need to reconsider the value of primary prevention of traveler’s diarrhea (TD) with antibiotics.


Randomized, placebo-controlled, double-blind studies evaluating the effectiveness and safety of rifaximin or a fluoroquinolone chemoprophylaxis against TD were pooled using a random effects model and assessed for heterogeneity.


The nine studies (four rifaximin and five fluoroquinolone) included resulted in pooled relative risk estimates of 0.33 (95% CI = 0.24–0.45, I2 = 3.1%) and 0.12 (95% CI = 0.07–0.20, I2 =0.0%), respectively. Similar rates of treatment emergent adverse events were found between antibiotic and placebo groups.


This meta-analysis supports the effectiveness of antibiotics in preventing TD. However, further studies that include prevention of secondary chronic health outcomes among travelers to different geographic regions, and a formal risk-benefit analysis for antibiotic chemoprophylaxis, are needed.

Travelers’ diarrhea; Chemoprophylaxis; Systematic review; Meta-analysis; Rifaximin; Fluoroquinolone